PBA
AMLX icon

Paradigm Biocapital Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,900,000
Closed -$25.8M – 34
2025
Q3 		$25.8M Buy
+1,900,000
New +$17.9M 0.73% 30

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Paradigm Biocapital Advisors's AMLX Position: Q4 2025 in Review

Paradigm Biocapital Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2025, closing a stake of 1,900,000 shares — an estimated $25.8M sold.

Paradigm Biocapital Advisors first reported a position in AMLX in Q3 2025 and held it in 1 quarter. The position peaked at $25.8M in Q3 2025. 179 funds tracked by Wall St. Rank hold AMLX as of Q4 2025.

  • Paradigm Biocapital Advisors reported no remaining Amylyx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,900,000 Amylyx Pharmaceuticals shares in Q4 2025, an estimated $25.8M.
  • Paradigm Biocapital Advisors first reported a position in Amylyx Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Amylyx Pharmaceuticals position peaked at $25.8M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.